

Long-term follow-up after pediatric hematopoietic stem cell transplantation

Polliany Roberta Dorini Pelegrina^{1*} , Roseane Vasconcelos Gouveia^{2,3} , Antonio Vaz de Macedo^{4,5,6} , Ana Karine Vieira^{7,8} , Gabriela Gaspar Filgueiras Landi⁹ , Julia Lopes¹⁰ , Osvaldo Alves de Menezes Neto^{11,12} , Rafaela de Souza Ferreira¹³ , Adriana Aparecida Siviero Miachon^{3,14,15} , Rita de Cássia Barbosa da Silva Tavares¹⁶ , Carmem Bonfim¹ 

1. Hospital Pequeno Príncipe – Curitiba (PR), Brazil.
2. Hospital Samaritano Higienópolis  – São Paulo (SP), Brazil.
3. Universidade Federal de São Paulo  – São Paulo (SP), Brazil.
4. Hospital da Polícia Militar – Belo Horizonte (MG), Brazil.
5. Hospital Luxemburgo – Belo Horizonte (MG), Brazil.
6. Instituto de Oncologia Ciências Médicas – Belo Horizonte (MG), Brazil.
7. Universidade Federal de Minas Gerais  – Belo Horizonte (MG), Brazil.
8. Santa Casa de Belo Horizonte  – Belo Horizonte (MG), Brazil.
9. Hospital da Criança e Maternidade – São José do Rio Preto (SP), Brazil.
10. Hospital Israelita Albert Einstein  – São Paulo (SP), Brazil.
11. Universidade Federal de Sergipe  – Aracaju (SE), Brazil.
12. Hospital São Lucas – Aracaju (SE), Brazil.
13. Hospital de Câncer de Barretos  – Barretos (SP), Brazil.
14. Grupo de Apoio ao Adolescente e à Criança com Câncer  – São Paulo (SP), Brazil.
15. Associação para Crianças e Adolescentes com Câncer – São Paulo (SP), Brazil.
16. Instituto Nacional do Câncer  – Rio de Janeiro (RJ), Brazil.

*Corresponding author: polliany.pelegrina@gmail.com

Section editor: Fernando Barroso Duarte 

Received: Aug. 30, 2025 • Accepted: Sept. 23, 2025

ABSTRACT

This article, part of the Pediatric Group consensus of the Brazilian Society of Bone Marrow Transplantation, addresses lifelong follow-up in pediatric hematopoietic stem cell transplant survivors. With the growing number of long-term survivors, specialized monitoring is essential, especially for high-risk groups such as infants, recipients of total body irradiation, and those with inherited bone marrow failure syndromes. The consensus outlines surveillance strategies for detecting and managing late complications, including chronic graft-versus-host disease and secondary effects. Multidisciplinary recommendations aim to optimize early intervention and quality of life, establishing a standardized follow-up framework for pediatric transplant care in Brazil.

Keywords: Follow-Up Studies. Cancer Survivors. Long Term Adverse Effects. Pediatrics.

INTRODUCTION

As the number of long-term transplant survivors continues to grow, comprehensive lifelong follow-up is crucial. These patients, especially those with specific considerations such as infants, individuals who received total body irradiation or have inherited bone marrow failure syndromes, face elevated risks of late complications. Therefore, dedicated long-term monitoring is essential for early detection and management of potential issues, including chronic graft-versus-host disease and other late effects.

Period	Category	Exam / Evaluation	Frequency
180 days	Laboratory	Complete blood count	At each visit
		Renal function	At each visit
		Liver function	At each visit
		Lipid profile, blood glucose, fasting insulin, HbA1c	Every 6 months
		Ferritin	Every 6 months
		Microalbuminuria	Every 6 months
		Vitamin D	Every 6 months
		Immunoglobulin levels	Every 6 months
	Imaging	Thyroid evaluation	Every 6 months
		Echocardiogram and ECG	Every 6 months
		Spirometry	Every 6 months
	Specialist	Dental evaluation	Every 6 months
		Pediatric endocrinologist	Referral
		Vaccination schedule (and check immune response later)	To be initiated and evaluated
360 days	Laboratory	Complete blood count	At each visit
		Renal function	At each visit
		Liver function	At each visit
		Lipid profile, blood glucose, fasting insulin, HbA1c	Annually
		IGF-1 / Somatomedin C	Annually
		Gonadal evaluation (FSH, LH, testosterone, estrogen)	Annually
		Ferritin	Annually
		Microalbuminuria	Annually
		Vitamin D	Once
		Thyroid evaluation	Annually
	Imaging	Serologies (HIV, HTLV, syphilis, Chagas, hepatitis B/C, etc.)	Once
		X-ray for bone age	Annually
		Pelvic ultrasound	Annually
		Thyroid ultrasound	Annually
		Echocardiogram and ECG	Annually
		Spirometry	Once
		Bone densitometry	Then annually
	Specialist	Dental evaluation	Then annually
		Ophthalmologist	Annually
		Pediatric cognitive assessment	Annually

This schedule is a general suggestion. Each case should be individualized according to clinical condition and patient needs, with adjustments in exam frequency as appropriate.

Parameter/test	Frequency	Notes	Recommendations
Ocular complications post-hematopoietic stem cell transplantation ^{1–4}			
Ophthalmological assessment	Annual or earlier in the presence of symptoms	Risk factors: TBI and corticosteroid therapy	Question about eye concerns
		IOP monitoring important in patients receiving any form of glucocorticoid	
		Risk of premature cataracts for TBI recipients—treatment is surgical, typically indicated in bilateral cases	
Oral and dental complications post-hematopoietic stem cell transplantation ^{5–10}			
Dental evaluation	6 and 12 months old. Then annually	Earlier and more frequent evaluation to be considered in high-risk patients (refractory chronic GVHD, cranial/neck radiation, Fanconi anemia, Diamond-Blackfan anemia) Perform oral and radiological assessment for tooth development	Screen for chronic GVHD, high-risk habits (smoking, vape, tobacco)
Bone complications post-hematopoietic stem cell transplantation ^{8–10}			
DEXA	Annual DXA scans recommended for all hematopoietic stem cell transplantation recipients with follow-up frequency determined by results	DXA provides dual benefit: bone mass assessment and body composition analysis (fat and lean mass)	Screen for hormonal factors that may impair bone health (hypogonadism/growth hormone deficiency)
			Implement lifestyle interventions: adequate nutrition, appropriate physical activity, and controlled sun exposure when permitted
			Ensure sufficient calcium and vitamin D intake
			Bisphosphonate therapy for severe cases—endocrinologist-guided treatment
Infectious complications post-hematopoietic stem cell transplantation ^{8,10,11}			
Pneumocystis jirovecii	Mandatory prophylaxis for ≥ six months post-transplantation or until immunosuppression discontinuation		
Varicella-zoster and herpes simplex virus	Duration: first year post-hematopoietic stem cell transplantation or until eight months after immunosuppression (IS) cessation (whichever is later)		
Encapsulated bacteria	Chronic GVHD: long-term chemoprophylaxis recommended due to unreliable vaccine protection. First-line: trimethoprim-sulfamethoxazole. Alternative: oral penicillin V (if trimethoprim-sulfamethoxazole intolerance). Supplemental medication required for <i>Pneumocystis jirovecii</i> pneumonia prophylaxis when using penicillin		For at least six months after discontinuation of all IS medications.
			Post-hematopoietic stem cell transplantation asplenic patients with chronic GVHD: prophylaxis until six months after IS or until 6 years old or two years after splenectomy (whichever occurs last)
			Post-hematopoietic stem cell transplantation asplenic patients without chronic GVHD: one year after transplantation or until 6 years old or two years after splenectomy (whichever occurs last)
			Sickle cell anemia: daily prophylactic penicillin for two years post-hematopoietic stem cell transplantation OR until 10 years old (whichever is longer); antibody titers should be assessed following post-transplant revaccination
CMV	Prophylaxis	Letermovir: effective for CMV-seropositive recipients (R+) until D+100 post-transplant. May extend to D+200 in selected cases	
Fungal infections	Prophylaxis	Duration: fluconazole until D+75 post-hematopoietic stem cell transplantation	
		GVHD cases: prophylaxis recommended when immunosuppression includes corticosteroids (≥ 0.3 mg/kg/day prednisone equivalent)	

Gastrointestinal and hepatic complications post-hematopoietic stem cell transplantation^{9,10,12-15}

Recommendations	Ask about gastrointestinal symptoms of GVHD at follow-up visits
	Monitor liver function by checking total bilirubin, alkaline phosphatase, and alanine aminotransferase (ALT) every one or two months during the first-year post-transplant, then annually for allo-hematopoietic stem cell transplantation recipients without liver disorder risk factors. Also evaluate ferritin levels to assess for possible iron overload
	Patients with pre-transplant indicators of hepatitis B (testing positive for HBsAg or anti-HBc) or those receiving stem cell from hepatitis B-infected donors face a risk of developing fulminant hepatitis B post-transplant if antiviral prophylaxis is not administered. These patients should receive prophylactic antiviral treatment
	Hepatitis C infected patients: consider diagnosis of fulminant immune-rebound hepatitis, particularly during IS tapering. When clinically indicated, implement treatment with antiviral drugs. Patients with chronic hepatitis B and C should receive follow-up care with a hepatologist
	HBsAg testing or viral load quantification (polymerase chain reaction) for hepatitis B and C should be performed at least one year after transplantation
Post-transplant diarrhea	Evaluation criteria: duration, volume, blood presence, fever, concurrent symptoms
	Differential diagnosis: GVHD, medication effects (especially magnesium supplementation), viral infections (varicella zoster, herpes simplex, CMV, adenovirus, rotavirus, norovirus and others), enteric pathogens (bacterial pathogens, giardiasis, cryptosporidiosis)
	Pancreatic abnormalities, though uncommon, should be considered in patients presenting with steatorrhea and weight loss. Evaluation for pancreatic insufficiency is essential, which may result from GVHD or medication toxicity, particularly tacrolimus

Iron overload¹⁶⁻¹⁸

Diagnosis	Serum ferritin: indirect marker of iron overload; influenced by inflammation and infection. Monitor every three to six months during the first year and/or during treatment
	Transferrin saturation: assesses iron binding capacity. Monitor every three to six months during the first year and/or during treatment
	T2-MRI (liver/heart)*: most sensitive technique to detect iron deposits in organs. If ferritin > 1,000 ng/mL, annual after engraftment
	Liver biopsy confirms excessive iron deposits in cases of uncertain diagnosis, rarely used
Treatment	Phlebotomy Most effective in patients with adequate hemoglobin levels (≥ 10 g/dL) and stable engraftment. It can be performed every 20–30 days. The volume per session ranges from 4 to 7 mL/kg, depending on patient tolerance, with a maximum limit of 400 mL
	Iron chelators Deferoxamine (SQ, IM, or IV): 1,000–2,000 mg SQ daily; 500–1,000 mg IM daily; 40–50 mg/kg IV daily
	Deferiprone oral tablets (with or without food): 75 mg/kg (typically 25 mg/kg three times daily) Deferasirox (oral tablets): Exjade (20 mg/kg daily, dissolved in liquids) or Jadenu (14 mg/kg daily). Both on an empty stomach or with a light meal (Jadenu)

Neurological complications^{7,9,10,19-25}

Recommendations	Perform childhood cognitive developmental milestones $\geq$ annually. Some children, especially those given TBI before the transplant, may have learning disabilities (particularly in mathematics and abstract thinking)
	Neurocognitive testing and educational/vocational progress assessment in pediatric survivors
	Neurological examination should be performed in all bone marrow transplant patients
	Audiologic evaluation: within first year post-hematopoietic stem cell transplantation
	Clinical assessment for peripheral nervous system and central nervous system dysfunction, especially in patients with GVHD

Endocrinological complications post-hematopoietic stem cell transplantation ^{5,8–10,26,27}			
Growth hormone deficiency	Risk factors	Young age at diagnosis/treatment, radiotherapy: cranial ≥ 18 Gy (especially > 30 Gy) or TBI, hypothalamic-pituitary tumors or surgery near sellar region and medications: prolonged glucocorticoids, TKI, isotretinoin, hedgehog inhibitors	
	Clinical monitoring	Assess weight, height, body mass index, growth velocity at every visit; evaluate pubertal stage (Tanner) at every visit; check body proportions annually if patient received spinal irradiation	
	Initial workup (for growth deficit/decreased velocity)	Bone age, thyroid function (TSH, free T4), IGF-1, growth hormone stimulation test	
	Growth hormone deficiency diagnostic criteria	Clinical: reduced growth velocity (< -2 SD/1 year or < -1.5 SD/2 years); laboratory: normal thyroid function, low IGF-1, inadequate growth hormone response to stimulation; radiological: normal magnetic resonance imaging or decreased pituitary; additional: other pituitary deficiencies and/or history of cranial radiotherapy, two growth hormone stimulation tests showing growth hormone peak < 5 ng/mL (only one test needed for radiotherapy patients)	
	Treatment	Should be carried out under the guidance of a pediatric endocrinologist. Initiate after one year from the end of oncological treatment. Daily subcutaneous recombinant growth hormone (rGH). Confirm absence of active disease, or stable disease. Consider safety, risks, and benefits: risk of recurrence of the underlying disease (low and inherent to the disease) and second malignant neoplasm (decreases with time and is associated with radiotherapy use). Monitor growth and adverse events	
Thyroid alterations	Annually: physical examination, thyroid function tests, and thyroid ultrasound	In case of alterations, request for hypothyroidism: anti-thyroperoxidase and anti-thyroglobulin; hyperthyroidism: anti-thyroperoxidase, anti-thyroglobulin, and TSH receptor antibody (TRAb) levels	Treatment of post-radiotherapy hypothyroidism and papillary carcinoma is similar to that of the general population.
Gonadal dysfunction	Monitor Tanner stages at each visit, in females: track menarche/menstrual cycles; measure FSH/LH and conduct pelvic ultrasonography (uterine volume, estrogenic activity) for ages > 12–13; in males: measure LH, FSH, and total testosterone for ages > 13–14. Pediatric endocrinology follow-up essential for hormone replacement based on height/bone age. For thrombosis-risk females, prioritize transdermal hormone replacement		
Fertility	Low fertility rates in post-transplant adolescents. Refer patients wanting pregnancy to fertility specialists. In adolescents: assess sexual activity, address difficulties, emphasize contraception despite fertility uncertainties		
Adrenal insufficiency	Evaluate HPA axis function (ACTH, cortisol) in patients on prolonged corticosteroids, assess recovery to determine if physiological doses can be discontinued, provide written instructions to affected patients to double medication during fever, trauma, or surgical procedures		
Obesity and metabolic syndrome	Monitor annually: body mass index, blood pressure, and abdominal circumference, as well as glucoses, basal insulin, lipid profile, and glycated hemoglobin levels. Follow-up with endocrinologist and pediatric cardiologist according to clinical and/or laboratory alterations		
Vitamin supplementation	Recommended for one year or until immunosuppression discontinuation (iron-free)		
	Vitamin D	Replacement: levels 20–30 ng/mL: < 1 year (400 IU/day), 1–8 years (600 IU/day), 9–18 years (800 IU/day), levels < 20ng/mL: 1–12 months (1,000–2000 IU/day for eight weeks), 1–18 years (1,000–5,000 IU/day or 50,000 mcg/week)	
		Check 25OH vitamin D after three months; repeat treatment if < 30 ng/mL	
Magnesium	Replacement necessary for all patients using IS (cyclosporine and tacrolimus)		
Post-hematopoietic stem cell transplantation pulmonary complications ^{10,26,28,29}			
Recommendations	Pulmonary function test screening protocol: perform every three months in first year post-hematopoietic stem cell transplantation, every six months in second year, then annually for five years (or until final adult height in pediatric patients). For children under 6 years old unable to perform standard pulmonary function tests, consider alternative screening methods including pulse oximetry, multiple breath washout testing, or parametric mapping by computed tomography		
	Computed tomography chest imaging: at onset of pulmonary symptoms or if abnormal pulmonary function test		
	Preventive measures: discourage smoking/vaping and recommend pneumococcal vaccination		
	For chronic GVHD patients: pulmonary function tests at diagnosis and quarterly until IS ends		
	Children who have received TBI have an increased risk of developing restrictive lung disease later in life, 5–20 years after hematopoietic stem cell transplantation: perform pulmonary function test annually on an ongoing basis		
	Clinical assessment for respiratory symptoms at every visit		

Cardiovascular complications post-hematopoietic stem cell transplantation^{10,30–32}

Recommendations	Blood pressure measurement at all consultations
	Prevention through lifestyle modifications: tobacco avoidance, exercise, diet, weight management
	Post-hematopoietic stem cell transplantation: regular electrocardiogram and echocardiography (three, six, 12 months, then annually)
	GVHD patients: more frequent monitoring (every three months), due to the increased risk of dysrhythmias, endothelial injury, and pericardial effusion
	Metabolic syndrome increases cardiovascular risk. Assessment and control of obesity, hypertension and disorders of glycemia, cholesterol and triglycerides
	Regular ferritin level checks with intervention if elevated and cardiac magnetic resonance imaging for specific cases

Post-hematopoietic stem cell transplantation revaccination^{10,33–38}

Patient immunity	Hematopoietic stem cell transplantation patients (autologous/allogeneic) lose previous immunity and require complete revaccination
Vaccine response	Returns to near-normal two or three years post-hematopoietic stem cell transplantation; patients have lower response rates due to incomplete immune reconstitution, immunosuppression, GVHD
Vaccination access	Special vaccines available at CRIEs (reference centers); some vaccines only available privately
Vaccination restart timing	Inactivated vaccines can be used as early as three months post-hematopoietic stem cell transplantation, as immunogenic vaccines show substantial response rates at this timepoint
Household contact vaccination	CRIEs provide influenza, varicella and MMR vaccines for susceptible household members. Oral polio vaccine is contraindicated for household members. Inactivated polio vaccine should be used instead when polio protection is needed
Chronic GVHD considerations	Patients require additional doses due to inadequate immune response: fourth dose of hepatitis B vaccine, fourth dose of 13- or 15-valent pneumococcal vaccine, second dose of influenza vaccine (regardless of age)
Check these links for more information	https://www.hematolog.app/imunizacao/
	https://www.gov.br/saude/pt-br/vacinacao/informes-tecnicos/informe-tecnico-vacina-covid-xbb/view
	https://sbim.org.br/images/calendarios/calend-sbim-crianca.pdf
	https://sbim.org.br/images/calendarios/manual-dos-centros-de-referencia-para-imunobiologicos-especiais-6a-edicao-2023.pdf

Psychological^{10,39–41}

Professional support	Ensure access to psychologists specialized in hematopoietic stem cell transplantation patients
Pre-transplant preparation	Implement routine psychological consultations before procedure
Address common issues	Target anxiety, post-traumatic stress disorder, depression, fatigue, and sleep disturbances
Focus on positive psychology	Promote optimism, gratitude, hope, and perseverance
Special attention to young adults	Provide additional support for employment and social reintegration
Regular monitoring	Review symptoms, distress, medications, and physical activity at each follow-up (minimum: D+100, D+180, D+365, then annually)
Standardized screening	Use mental health questionnaires regularly
Medication adherence	Discuss and provide educational support
Lifestyle guidance	Set goals for healthy diet, activity, and weight management
Caregiver support	Monitor psychological adjustment of spouse/caregiver and family functioning
Reintegration assistance	Help with return-to-work/school programs; provide healthcare education for adolescents and young adults patients
Holistic approach:	Encourage adequate sleep and age-appropriate preventive measures

Renal complications ^{10,42-49}	
Chronic kidney disease	eGFR ≤ 60 mL/min/1.73 m ² calculated from serum creatinine for at least three months or more
	Risk factors: previous AKI/hypertension, baseline dysfunction, GVHD, older age, allogeneic transplant, myeloablative conditioning, nephrotoxic drugs, specific infections, and diagnosis
	General screening: UA, rUPCR, BUN and creatinine levels every three months in the first year and $\geq$ yearly thereafter. Shorter interval if abnormal values or complications
Transplant-associated thrombotic microangiopathy	After D+100 weekly screening if severe GVHD or infections
	Screening presence $\geq$ three of the following: anemia, thrombocytopenia, elevated LDH, proteinuria (≥ 1 mg/mg rUPCR), schistocytes, refractory HTN requires additional testing
	High-risk TA-TMA: any of following: elevated sC5b9, rUPCR ≥ 1 mg/mg, organ dysfunction (except KDIGO stage I), LDH ≥ 2 x ULN, concurrent GVHD 2-4, or infections
Nephrotic syndrome	Proteinuria (≥ 2 g) or albuminuria > 3.5 g/24 h; edema; hypoalbuminemia; hypercholesterolemia; lipiduria
Hypertension	Lifestyle changes and antihypertensive therapy to reduce risks of cardiovascular and CKD
Secondary malignancies ^{9,10,26,50,51}	
Increased risk	Skin cancers, solid tumors, myelodysplastic syndromes, leukemias, and post-transplant lymphoproliferative disorder
Recommendations	Skin exam with the complete physical examinations and clinical history
	Pap smears and mammogram (women aged 25 or eight-years post-radiotherapy, whichever occurs later, but no later than age 40) and education to reinforce self-breast exams. Prostate exam and prostate-specific antigen (men > 45 years). Occult blood in stool (> 40 years) and colonoscopy (baseline at age 50, in absence of a family history, and as clinically indicated thereafter)
	Oral exam by the dentist at six-month intervals
	Regular thyroid ultrasound; fine needle aspiration in case of suspicious nodule (patients at risk: after TBI or local radiation)
	Complete blood counts, thyroid function, and other tests as applicable
	Patients with inherited bone marrow failure syndromes have a higher risk of solid cancers. Fanconi anemia survivors with mutations in BRCA2 (FANCD1) or PALB2 (FANCN) require screening for specific solid cancers (including leukemias, brain tumors, and childhood-onset solid tumors)
	Consider meningioma screening in patients who received central nervous system radiotherapy
	All patients should use sun blocking creams or sunscreens (> 30 sun protection factor) when outdoors to prevent skin cancers and to prevent activation of chronic GVHD
	Encourage to avoid high-risk behaviors, unhealthy diet (e.g., tobacco and vaping, passive tobacco exposure, alcohol abuse, high fat/low fiber diet)
Post-transplant proliferative disorder ⁵¹⁻⁶¹	
Risk factor	Main risk factors: EBV status and T-cell immunosuppression; highest risk: pediatric patients with negative EBV status; risk-increasing agents: ATG, anti-CD52 (alemtuzumab); risk-reducing agent: post-transplant cyclophosphamide
Classification	Plasmacytic hyperplasia, infectious mononucleosis-like, florid follicular hyperplasia, polymorphic, monomorphic (B-cell or T-/NK-cell types), and classical Hodgkin lymphoma post-transplant proliferative disorder
Diagnostic evaluation	Positron emission tomography/computed tomography: highly sensitive for identifying active disease and guiding biopsy sites
	Magnetic resonance imaging: preferred for central nervous system involvement assessment
	Ultrasound: useful for detecting abdominal masses or lymphadenopathy
Treatment strategies	Reduction of immunosuppression: first-line approach in stable patients
	Rituximab (anti-CD20): effective in EBV-driven B-cell post-transplant proliferative disorder. Dose: 375 mg/m ² intravenously weekly for four doses
	Chemotherapy: indicated for aggressive or refractory cases
	EBV-specific cytotoxic T cells: emerging therapy with promising outcomes
	Antiviral therapy: Limited role but may be combined with other treatments

TBI: total body irradiation; IOP: intraocular pressure; GVHD: graft versus host disease; DXA: dual-energy X-ray absorptiometry/bone densitometry; *for more information on diagnosis, treatment, and monitoring, refer to the chapter on infectious complications; CMV: cytomegalovirus; SQ: subcutaneous; IM: intramuscular; IV: intravenous; Gy: gray; TKI: tyrosine kinase inhibitors; TSH: thyroid-stimulating hormone; IGF-1: insulin-like growth factor 1; SD: standard deviation; FSH: follicle-stimulating hormone; LH: luteinizing hormone; HPA: hypothalamic-pituitary-adrenal; ACTH: adrenocorticotropic hormone; CRIE: Reference Center for Special Immunobiologicals; MMR: measles, mumps and rubella; eGFR: estimated glomerular filtration rate; AKI: acute kidney injury; UA: urine analysis; rUPCR: urine protein-to-creatinine ratio; BUN: blood urea nitrogen; LDH: lactate dehydrogenase test; TA-TMA: transplant-associated thrombotic microangiopathy; sC5b-9 is not available in most Brazilian centers; sC5b9: soluble complement C5 fraction b-9; KDIGO: Kidney Disease: Improving Global Outcomes; ULN: upper limit of normal; HTN: hypertension; CKD: chronic kidney disease.

CONFLICT OF INTEREST

Nothing to declare.

DATA AVAILABILITY STATEMENT

All dataset are presented/analysed in the text.

AUTHORS' CONTRIBUTIONS

Substantive scientific and intellectual contributions to the study: Pelegrina PRD, Gouveia RV, Macedo AV, Vieira AK, Landi GGF, Lopes J, Menezes Neto OA, Ferreira RS, Miachon AAS, Tavares R, Bonfim C. **Conception and design:** Pelegrina PRD, Gouveia RV, Macedo AV, Vieira AK, Landi GGF, Lopes J, Menezes Neto OA, Ferreira RS, Miachon AAS, Tavares R, Bonfim C. **Analysis and interpretation of data:** Pelegrina PRD, Gouveia RV, Macedo AV, Vieira AK, Landi GGF, Lopes J, Menezes Neto OA, Ferreira RS, Miachon AAS, Tavares R, Bonfim C. **Manuscript writing:** Pelegrina PRD, Gouveia RV, Macedo AV, Vieira AK, Landi GGF, Lopes J, Menezes Neto OA, Ferreira RS, Miachon AAS, Tavares R, Bonfim C. **Final approval:** Pelegrina PRD.

FUNDING

Not applicable.

ACKNOWLEDGMENTS

We thank Society of Bone Marrow Transplantation and all authors who actively participated in this review, and we dedicate this article to all our patients, thanking them for their trust and perseverance, and to the entire multidisciplinary team that actively participates in the care of these children.

REFERENCES

1. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini MT, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Petříček I. Non-graft-versus-host disease ocular complications after hematopoietic cell transplantation: expert review from the late effects and quality of life working committee of the center for international blood and marrow transplant research and the transplant complications working party of the European society for blood and marrow transplantation. *Biol Blood Marrow Transplant*. 2019;25(2):e46-e54. <https://doi.org/10.1016/j.bbmt.2018.11.021>
2. Lee SL, Nguyen QN, Ho C, James S, Kaur A, Lim A, Tiedemann K, Zacharin M. The late effects of hematopoietic stem cell transplants in pediatric patients: a 25-year review. *J Clin Endocrinol Metab*. 2025;110(2):e347-62. <https://doi.org/10.1210/clinem/dgae196>
3. Hoehn ME, Vestal R, Calderwood J, Gannon E, Cook B, Rochester R, Hartford C, Triplett B, Sunkara A, Kang G, Walton RC. Ocular complications in school-age children and adolescents after allogeneic bone marrow transplantation. *Am J Ophthalmol*. 2020;213:153-60. <https://doi.org/10.1016/j.ajo.2020.01.025>
4. Hoehn ME, Calderwood J, Gannon E, Cook B, Rochester R, Hartford C, Triplett B, Sunkara A, Kang G, Walton RC. Ocular complications in a young pediatric population following bone marrow transplantation. *J Am Assoc Pediatr Ophthalmol Strabismus*. 2018;22(2):102-106.e1. <https://doi.org/10.1016/j.jaapos.2017.10.010>

5. van der Pas-van Voskuilen IG, Veerkamp JS, Raber-Durlacher JE, Bresters D, van Wijk AJ, Barasch A, McNeal S, Gortzak RA. Long-term adverse effects of hematopoietic stem cell transplantation on dental development in children. *Support Care Cancer*. 2009;17(9):1169-75. <https://doi.org/10.1007/s00520-008-0567-1>
6. Haverman TM, Raber-Durlacher JE, Rademacher WM, Vokurka S, Epstein JB, Huisman C, Hazenberg MD, de Soet JJ, de Lange J, Rozema FR. Oral complications in hematopoietic stem cell recipients: the role of inflammation. *Mediators Inflamm*. 2014;2014:378281. <https://doi.org/10.1155/2014/378281>
7. Majhail NS, Rizzo JD. Surviving the cure: long term followup of hematopoietic cell transplant recipients. *Bone Marrow Transplant*. 2013;48(9):1145-51. <https://doi.org/10.1038/bmt.2012.258>
8. Fred Hutchinson Cancer Center. Long-term follow-up after hematopoietic stem cell transplant: general guidelines for referring physicians. Seattle: Fred Hutchinson Cancer Center; 2024.
9. Lopes Garcia J, Vaz De Macedo A, Dorini Pelegrina PR, Barbosa Tavares RDC, Vasconcelos Gouveia R, Seber A. Long-term follow-up of pediatric patients undergoing hematopoietic stem cell transplantation. *J Bone Marrow Transplant Cell Ther*. 2021;2(4):142. <https://doi.org/10.46765/2675-374X.2021v2n4p142>
10. Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, Beebe K, Buchbinder D, Burkhard P, Carpenter PA, Chaudhri N, Elemary M, Elsayy M, Guilcher GM, Hamad N, Karduss A, Peric Z, Purtill D, Rizzo D, Rodrigues M, Ostriz MBR, Salooja N, Schoemans H, Seber A, Sharma A, Srivastava A, Stewart SK, Baker KS, Majhail NS, Phelan R. International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update. *Bone Marrow Transplant*. 2024;30(4):349-85. <https://doi.org/10.1016/j.jtct.2023.12.001>
11. Galaverna F, Baccelli F, Zama D, Tridello G, Masetti R, Soncini E, Mura R, Barzaghi F, Colombini A, Prunotto G, D'Amico MR, Calore E, Biffi A, Perruccio K, Gasperini P, Oltolini C, Quagliarella F, Giacomazzi A, Pagliara D, Locatelli F, Cesaro S. Letemovir for Cytomegalovirus infection in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (IEOP). *Bone Marrow Transplant*. 2024;59(4):505-12. <https://doi.org/10.1038/s41409-024-02209-2>
12. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. *Biol Blood Marrow Transplant*. 2005;11(12):945-56. <https://doi.org/10.1016/j.bbmt.2005.09.004>
13. Campo LD, León NG, Palacios DC, Lagana C, Tagarro D. Abdominal complications following hematopoietic stem cell transplantation. *RadioGraphics*. 2014;34(2):396-412. <https://doi.org/10.1148/rg.342135046>
14. Strasser SI, Shulman HM, Flowers ME, Reddy R, Margolis DA, Prumbaum M, Seropian SE, McDonald GB. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. *Hepatology*. 2000;32(6):1265-71. <https://doi.org/10.1053/jhep.2000.20067>
15. Gentile G, Antonelli G. HBV reactivation in patients undergoing hematopoietic stem cell transplantation: a narrative review. *Viruses*. 2019;11(11):1049. <https://doi.org/10.3390/v11111049>
16. Nava T, Ansari M, Dalle JH, de Heredia CD, Güngör T, Trigos E, Falkenberg U, Bertaina A, Gibson B, Jarisch A, Balduzzi A, Boenig H, Krivan G, Vettenranta K, Matic T, Buechner J, Kalwak K, Lawitschka A, Yesilipek A, Lucchini G, Peters C, Turkiewicz D, Niinimäki R, Diesch T, Lehrnbecher T, Sedlacek P, Hutt D, Dalissier A, Wachowiak J, Yaniv I, Stein J, Yalçin K, Sisinni L, Deiana M, Ifversen M, Kuhlen M, Meisel R, Bakhtiar S, Cesaro S, Willasch A, Corbacioglu S, Bader P. Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant*. 2020;55(6):1126-36. <https://doi.org/10.1038/s41409-020-0818-4>

17. Cattoni A, Capitoli G, Casagrande S, Corti P, Adavastro M, Molinaro A, Di Gennaro F, Bonanomi S, Biondi A, Galimberti S, Balduzzi A. Iron overload following hematopoietic stem cell transplantation: prevalence, severity, and management in children and adolescents with malignant and nonmalignant diseases. *Transplant Cell Ther.* 2023;29(4):271.e1-271.e12. <https://doi.org/10.1016/j.jtct.2023.01.020>
18. Tenneti P, Chojecki A, Knovich MA. Iron overload in the HCT patient: a review. *Bone Marrow Transplant.* 2021;56(8):1794-804. <https://doi.org/10.1038/s41409-021-01244-7>
19. Dulamea A, Lupescu I. Neurological complications of hematopoietic cell transplantation in children and adults. *Neural Regen Res.* 2018;13(6):945-54. <https://doi.org/10.4103/1673-5374.233431>
20. Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ, Petryk A, Steinberger J, Anderson FS, Baker KS. Long-term follow-up of children who underwent hematopoietic cell transplant (HCT) for AML or ALL at less than 3 years of age. *Pediatr Blood Cancer.* 2007;49(7):958-63. <https://doi.org/10.1002/pbc.21207>
21. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A; Center for International Blood and Marrow Transplant Research; American Society for Blood and Marrow Transplantation; European Group for Blood and Marrow Transplantation; Asia-Pacific Blood and Marrow Transplantation Group; Bone Marrow Transplant Society of Australia and New Zealand; East Mediterranean Blood and Marrow Transplantation Group; Sociedade Brasileira de Transplante de Medula Ossea. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. *Bone Marrow Transplant.* 2012;47(3):337-41. <https://doi.org/10.1038/bmt.2012.5>
22. Dowling MR, Li S, Dey BR, McAfee SL, Hock HR, Spitzer TR, Chen YB, Ballen KK. Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. *Bone Marrow Transplant.* 2018;53(2):199-206. <https://doi.org/10.1038/bmt.2017.239>
23. Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, Sun C, Francisco L, Forman SJ, Wong FL, Bhatia S. Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: results from a prospective longitudinal study. *J Clin Oncol.* 2018;36(5):463-75. <https://doi.org/10.1200/jco.2017.74.2270>
24. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2018;24(2):228-41. <https://doi.org/10.1016/j.bbmt.2017.09.004>
25. Kang JM, Kim YJ, Kim JY, Cho EJ, Lee JH, Lee MH, Lee SH, Sung KW, Koo HH, Yoo KH. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors. *Biol Blood Marrow Transplant.* 2015;21(6):1091-8. <https://doi.org/10.1016/j.bbmt.2015.02.007>
26. Carreras E, Dufour C, Mohty M, Kröger N, editors. *The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies.* Cham: Springer International; 2019.
27. Sociedade Brasileira de Pediatria. Complicações endócrinas do tratamento oncológico na infância: informações para o pediatra. *Rev Med Minas Gerais.* 2010;20(4 Suppl. 3):S54-S58.

28. Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. *Clin Chest Med*. 2004;25(1):189-201. [https://doi.org/10.1016/s0272-5231\(03\)00121-7](https://doi.org/10.1016/s0272-5231(03)00121-7)
29. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datile MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. *Biol Blood Marrow Transplant*. 2015;21(3):389-401.e1. <https://doi.org/10.1016/j.bbmt.2014.12.001>
30. Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau JL, Masszi T, Zander A, Békássy A, Crawley C, Arat M, Sica S, Lutz P, Socié G; EBMT Late Effects Working Party. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2008;93(8):1203-10. <https://doi.org/10.3324/haematol.12949>
31. Tichelli A, Rovó A, Gratwohl A. Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices. *Hematology*. 2008:125-33. <https://doi.org/10.1182/asheducation-2008.1.125>
32. Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2009;43(1):49-54. <https://doi.org/10.1038/bmt.2008.263>
33. Brasil. Ministério da Saúde. Manual dos Centros de Referência para Imunobiológicos Especiais. 6ª ed. Brasília: Ministério da Saúde; 2024.
34. Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, de Lavallade H, Gallo G, Lehrnbecher T, Engelhard D, Ljungman P; European Conference on Infections in Leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). *Lancet Infect Dis*. 2019;19(6):e200-12. [https://doi.org/10.1016/s1473-3099\(18\)30600-5](https://doi.org/10.1016/s1473-3099(18)30600-5)
35. Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn EC. Vaccination of adults with cancer: ASCO Guideline. *J Clin Oncol*. 2024;42(14):1699-721. <https://doi.org/10.1200/jco.24.00032>
36. Schuster JE, Hamdan L, Dulek DE, Kitko CL, Batarseh E, Haddadin Z, Stewart LS, Stahl A, Potter M, Rahman H, Kalams SA, Bocchini CE, Moulton EA, Coffin SE, Ardura MI, Wattier RL, Maron G, Grimley M, Paulsen G, Harrison CJ, Freedman JL, Carpenter PA, Englund JA, Munoz FM, Danziger-Isakov L, Spieker AJ, Halasa NB; Pediatric HCT Flu Study. The durability of antibody responses of two doses of high-dose relative to two doses of standard-dose inactivated influenza vaccine in pediatric hematopoietic cell transplant recipients: a multi-center randomized controlled trial. *Clin Infect Dis*. 2024;78(1):217-26. <https://doi.org/10.1093/cid/ciad534>
37. Sociedade Brasileira de Imunizações. Calendário de vacinas para pacientes especiais. São Paulo: Sociedade Brasileira de Imunizações; 2024.
38. Maiolino MG, Carlesse F, Ramos JF. Prevention and treatment of infectious complications post HSCT. *J Bone Marrow Transplant Cell Ther*. 2021;2(1):197-217. <https://doi.org/10.46765/2675-374X.2021v4n1p197-217>
39. Association of Clinical Psychologists, Anthony Nolan. Guidelines for the role of psychological specialists in the assessment of adults undergoing haematopoietic stem cell transplantation. London: Anthony Nolan; 2024.
40. Amonoo HL, Brown LA, Scheu CF, Millstein RA, Pirl WF, Vitagliano HL, Antin JH, Huffman JC. Positive psychological experiences in allogeneic hematopoietic stem cell transplantation. *Psychooncology*. 2019;28(8):1633-9. <https://doi.org/10.1002/pon.5128>

41. Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjane A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B. Return to work among young adult survivors of allogeneic hematopoietic cell transplantation in the United States. *Transplant Cell Ther.* 2021;27(8):679.e1-679.e8. <https://doi.org/10.1016/j.jtct.2021.04.013>
42. Lugthart G, Jordans CCE, de Pagter APJ, Bresters D, Jol-van der Zijde CM, Bense JE, van Rooij-Kouwenhoven RWG, Sukhai RN, Louwerens M, Dorresteyn EM, Lankester AC. Chronic kidney disease ten years after pediatric allogeneic hematopoietic stem cell transplantation. *Kidney Int.* 2021;100(4):906-14. <https://doi.org/10.1016/j.kint.2021.05.030>
43. Hingorani S. Renal complications of hematopoietic-cell transplantation. *N Engl J Med.* 2016;374(23):2256-67. <https://doi.org/10.1056/nejmra1404711>
44. Renaghan AD, Costa JM, Esteves A. Kidney disease and hematopoietic stem cell transplantation. *Kidney360.* 2025;6(2):317-30. <https://doi.org/10.34067/kid.0000000692>
45. Higham CS, Shimano KA, Kharbanda S, Chu J, Cisneros GS, Winestone LE, Dara J, Huang JN, Hermiston ML, Long-Boyle JR, Dvorak CC. Cyclophosphamide and thiotepa increases risk of transplant-associated thrombotic microangiopathy. *Transplant Cell Ther.* 2024;30(9):931.e1-931.e10. <https://doi.org/10.1016/j.jtct.2024.06.020>
46. Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda A, Soiffer R, Vasu S. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. *Transplant Cell Ther.* 2023;29(3):151-63. <https://doi.org/10.1016/j.jtct.2022.11.015>
47. Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long-Boyle JR, Dvorak CC. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. *Blood Adv.* 2021;5(8):2106-12. <https://doi.org/10.1182/bloodadvances.2020003988>
48. Pan T, Qi J, Tang Y, Yao Y, Chen J, Wang H, Yang J, Xu X, Shi Q, Liu Y, He X, Chen F, Ma X, Hu X, Wu X, Wu D, Han Y. N-acetylcysteine as prophylactic therapy for transplantation-associated thrombotic microangiopathy: a randomized, placebo-controlled trial. *Transplant Cell Ther.* 2022;28(11):764.e1-764.e7. <https://doi.org/10.1016/j.jtct.2022.07.029>
49. Kwon DH, Jung S, Lee EJ, Lee JY, Moon S, Lee JW, Chung NG, Cho B, Kim HK. Incidence and risk factors for early-onset hypertension after allogeneic hematopoietic stem cell transplantation in children. *Korean Circ J.* 2013;43(12):804-10. <https://doi.org/10.4070/kcj.2013.43.12.804>
50. Bonfim C. Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes. *Hematology Am Soc Hematol Educ Program.* 2020;2020(1):107-14. <https://doi.org/10.1182/hematology.2020000095>
51. National Marrow Donor Program / BeThe Match. Post-Transplant Care. National Marrow Donor Program / Be The Match [cited 2025 Apr 30]. Available from: <https://network.nmdp.org/services-support/hematology-oncology/post-transplant-care>

52. Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders. *Cancer Treat Res*. 2015;165:305-27. https://doi.org/10.1007/978-3-319-13150-4_13
53. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. *Curr Hematol Malig Rep*. 2013;8(3):173-83. <https://doi.org/10.1007/s11899-013-0162-5>
54. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. *Crit Rev Oncol Hematol*. 2005;56(1):155-67. <https://doi.org/10.1016/j.critrevonc.2005.03.015>
55. McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, Wyatt R, Arar M, Liereman D, Bridges N, Harmon W; CCTPT Study Group. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. *Am J Transplant*. 2008;8(5):984-9. <https://doi.org/10.1111/j.1600-6143.2008.02167.x>
56. Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. *Blood*. 1999;94(7):2208-16.
57. Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches. *World J Transplant*. 2020;10(2):29-46. <https://doi.org/10.5500/wjt.v10.i2.29>
58. Ferreira JF, Morscio J, Dierickx D, Vandenberghe P, Gheysens O, Verhoef G, Zamani M, Tousseyn T, Wlodarska I. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. *Am J Transplant*. 2016;16(2):414-25. <https://doi.org/10.1111/ajt.13558>
59. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017.
60. Clerico M, Dogliotti I, Aroldi A, Consoli C, Giaccone L, Bruno B, Cavallo F. Post-transplant lymphoproliferative disease (PTLD) after allogeneic hematopoietic stem cell transplantation: biology and treatment options. *J Clin Med*. 2022;11(24):7542. <https://doi.org/10.3390/jcm11247542>
61. Marks DI, Davies AJ, Stiller C, van der Werff Ten Bosch J, Sienie CA, Ebell W, Veys P, Cohen A, Rao K, Ifrah N, Lehrnbecher T, Korthof E, Schellong G, Pilon M, Andolina M, Balduzzi A, Beauchemin H, Boelens JJ, Boztug H, Buechner J, Chevret S, Coman T, Diaz-de-Heredia C, Dvorak CC, Faraci M, Felice M, Furtwängler R, Gámez P, Gennery A, Greil J, Grigore E, Ifrah N, Locatelli F, Nöllke P, Peters C, Sakashita E, Simonova E, Slatter M, Stepensky P, Tse W, Veys P, Wimmer G, Winiarski J, Wynn R, Yoshimi A, Treleaven JG, Magrath IT, Norton AJ, Shannon-Lowe C. The use of rituximab in pediatric PTLD: a multicenter study. *Lancet Oncol*. 2018;19(3):347-57.